MYGN saw its Momentum Indicator move below the 0 level on December 09, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In of the 91 cases, the stock moved further down in the following days. The odds of a decline are at .
The 50-day moving average for MYGN moved below the 200-day moving average on November 15, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MYGN entered a downward trend on December 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for MYGN just turned positive on November 22, 2024. Looking at past instances where MYGN's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MYGN advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MYGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.460) is normal, around the industry mean (23.300). P/E Ratio (0.000) is within average values for comparable stocks, (83.485). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (2.357) is also within normal values, averaging (43.338).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
a developer of therapeutic and predictive medicine products
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with GMED. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then GMED could also see price increases.
Ticker / NAME | Correlation To MYGN | 1D Price Change % | ||
---|---|---|---|---|
MYGN | 100% | -2.12% | ||
GMED - MYGN | 39% Loosely correlated | +2.11% | ||
WAT - MYGN | 39% Loosely correlated | -0.08% | ||
VCYT - MYGN | 37% Loosely correlated | -2.52% | ||
MTD - MYGN | 36% Loosely correlated | -1.10% | ||
FLGT - MYGN | 36% Loosely correlated | -1.12% | ||
More |